Biofrontera reports preliminary revenue for the month of June 2021
Biofrontera AG (NASDAQ: BFRA) reported preliminary unaudited revenues of approximately EUR 2,626 thousand for June 2021, marking a significant 50% increase compared to EUR 1,701 thousand in June 2020. Sales in the US rose 11% to EUR 1,375 thousand, with strong growth of 770% in other European markets. Compared to June 2019, total product sales increased 19%, driven by 35% growth in Germany. However, US sales declined 10% due to lower sales of certain products. Overall, Q2 2021 showed a 10% increase in product sales versus Q2 2019.
- Total revenue in June 2021 increased by 50% year-over-year.
- Sales in other European markets surged by 770% compared to June 2020.
- Overall product sales in Q2 2021 grew by 10% compared to Q2 2019.
- US product sales decreased by 10% compared to June 2019.
- Decline attributed to lower sales of Aktipak® and Xepi®.
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of June 2021.
The Company’s preliminary, unaudited revenue from product sales in June 2021 amounted to approximately EUR 2,626 thousand, compared to EUR 1,701 thousand in June 2020, an increase of
Preliminary revenues from product sales in the US were around EUR 1,375 thousand compared to EUR 1,235 thousand in June 2020, an increase of
Preliminary unaudited revenues
| June | Q2 | |||||
| in EUR thousands | 2021 | 2020 | 2019 | 2021 | 2020 | 2019 |
| USA | 1,375 | 1,235 | 1,539 | 4,861 | 2,166 | 5,060 |
| Germany | 417 | 370 | 309 | 1,285 | 1,054 | 1,081 |
| Europe (ex Germany) | 834 | 96 | 361 | 1,448 | 146 | 793 |
| Total revenue from product sales | 2,626 | 1,701 | 2,199 | 7,595 | 3,366 | 6,934 |
| Revenues from R&D projects and license payments | 0 | 48 | 54 | 0 | 6,278 | 162 |
| Total revenue | 2,626 | 1,750 | 2,253 | 7,595 | 9,644 | 7,096 |
Due to commercial rounding, rounding differences may occur in tables.
Due to the pandemic, the monthly and quarterly sales development is compared with sales in 2019 for increased transparency. As such, an increase of
In Q2 2021, product sales in all markets were up by around
-End-
Biofrontera AG
Pamela Keck, Head of Investor Relations
ir@biofrontera.com
+49-214-87632-0
About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi® for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.
Forward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering.
These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the annual report on Form 20-F filed with the SEC, including Item 3.D. "Key Information - Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.
FAQ
What was Biofrontera AG's revenue for June 2021?
How much did Biofrontera AG's revenue increase year-over-year?
What were the sales figures for Biofrontera AG in the US for June 2021?
How did Biofrontera AG's sales perform compared to June 2019?
What trends were observed in Biofrontera AG's sales in Q2 2021?
